肝硬化治療市場規模、佔有率和成長分析（按疾病類型、治療類型、最終用戶和地區分類）—2026-2033年產業預測

全球肝硬化治療市場規模預計在 2024 年達到 189 億美元，從 2025 年的 201.1 億美元成長到 2033 年的 330.3 億美元，在預測期（2026-2033 年）內複合年成長率為 6.4%。

全球肝硬化治療市場正積極應對因生活方式改變、酒精消費量增加和不良飲食習慣而日益嚴峻的肝病挑戰。慢性肝病影響全球約15億人，其盛行率顯示對創新治療方案的需求不斷成長。乙型肝炎仍是肝硬化和肝細胞癌的主要病因，且與疾病相關的死亡率極高。影響市場成長的關鍵趨勢是全球肝病發生率的上升，尤其是非酒精性脂肪性肝病（NAFLD），預計其發病率將呈指數級成長。隨著全球對肝病的認知與診斷水準不斷提高，以及各大製藥公司大力投資研發新治療方法，市場正呈現擴張跡象。

全球肝硬化治療市場促進因素

肝病在全球的流行仍然是一個重大問題，主要原因包括久坐不動的生活方式、缺乏運動和不健康的飲食習慣。此外，人口老化以及肝炎和非酒精性脂肪肝（NAFLD）等自體免疫疾病的增加，導致需要治療的患者人數不斷增加。同時，酒精消費量的上升也加劇了肝病的發生率。隨著醫療機構努力滿足治療方法需求，預計透過與生物技術公司和研究機構合作，藥物和醫療設備研發方面的創新將推動肝病治療市場的發展。這種競爭格局將為相關人員創造眾多機遇，並推動市場成長。

全球肝硬化治療市場面臨的限制因素

全球肝硬化治療市場面臨許多重大挑戰，阻礙其成長。有效治療肝病所需的高昂藥物、治療和手術費用是市場發展的主要障礙。醫療資源匱乏，尤其是在農村和醫療服務不足的地區，加劇了這一問題，而公眾和醫療服務提供者對肝病及其症狀的認知不足則使情況更加惡化。此外，與酒精和細菌感染相關的某些肝病所存在的社會污名也使情況更加複雜。肝臟移植的挑戰、嚴格的監管要求以及研發開發平臺缺乏創新藥物也限制了市場發展。治療所需的高昂費用是限制整個市場發展的因素之一。

全球肝硬化治療市場趨勢

全球肝硬化治療市場正經歷顯著成長，這主要得益於研發投入的激增，這些投入旨在開發新的治療方案和改進診斷技術。人們對肝病的認知不斷提高，預防服務的普及以及治療資金的增加，凸顯了早期診斷和治療這些疾病的緊迫性。此外，人口老化、醫療基礎設施的改善以及新興市場可支配收入的成長等人口結構變化也促進了市場擴張。外科手術和非侵入性放射介入技術的進步進一步拓展了治療選擇，這些因素共同為創新肝病治療創造了有利環境。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球肝硬化治療市場規模（按疾病類型和複合年成長率分類）（2026-2033 年）

• 酒精性肝硬化
• 萎縮性肝硬化
• 膽汁性肝硬化
• 病因不明的肝硬化

全球肝硬化治療市場規模（按療法和複合年成長率分類）（2026-2033 年）

• 免疫抑制劑
• 抗生素
• 疫苗
• 抗病毒藥物
• 皮質類固醇

全球肝硬化治療市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院藥房
• 零售藥房
• 其他

全球肝硬化治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Gilead Sciences（United States）
• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Takeda Pharmaceutical Company Limited（Japan）
• AstraZeneca（United Kingdom）
• Bayer AG（Germany）
• Sanofi（France）
• AbbVie Inc.（United States）
• GlaxoSmithKline PLC（United Kingdom）
• Bristol-Myers Squibb Company（United States）
• Alnylam Pharmaceuticals Inc.（United States）
• Viking Therapeutics（United States）
• Galectin Therapeutics Inc.（United States）
• Akero Therapeutics, Inc.（United States）
• NGM Biopharmaceuticals, Inc.（United States）
• Poxel SA（France）

結論與建議

Global Liver Cirrhosis Treatment Market size was valued at USD 18.9 Billion in 2024 and is poised to grow from USD 20.11 Billion in 2025 to USD 33.03 Billion by 2033, growing at a CAGR of 6.4% during the forecast period (2026-2033).

The global liver cirrhosis treatment market is responding to increasing challenges posed by liver disease, driven by lifestyle changes, rising alcohol consumption, and poor dietary habits. The prevalence of chronic liver disease, which affects approximately 1.5 billion individuals worldwide, highlights the growing urgency for innovative therapeutic solutions. Hepatitis B remains a significant contributor to liver cirrhosis and hepatocellular carcinoma, with alarming mortality rates linked to the disease. Key trends influencing market growth include the increasing global incidence of liver conditions, particularly non-alcoholic fatty liver disease (NAFLD), which is expected to surge considerably. With major pharmaceutical companies investing heavily in research to develop new treatments, the market is poised for expansion as awareness and diagnosis of liver diseases continue to improve globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Cirrhosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Cirrhosis Treatment Market Segments Analysis

Global Liver Cirrhosis Treatment Market is segmented by Disease Type, Treatment Type, End User and region. Based on Disease Type, the market is segmented into Alcoholic Cirrhosis, Atrophic Cirrhosis, Biliary Cirrhosis and Cryptogenic Cirrhosis. Based on Treatment Type, the market is segmented into Immunosuppressants, Antibiotics, Vaccines, Anti-viral drugs and Corticosteroids. Based on End User, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liver Cirrhosis Treatment Market

The prevalence of liver disease continues to be a significant global concern, primarily due to factors such as sedentary lifestyles, inadequate physical activity, and poor dietary habits. This, combined with an aging population and the rise of autoimmune conditions like hepatitis and non-alcoholic fatty liver disease, has led to a growing number of patients requiring treatment. Furthermore, increasing alcohol consumption has contributed to the higher incidence of liver-related ailments. The market for liver disease treatments is expected to flourish as healthcare organizations respond to the demand for therapies, driving innovation in drug and device development through partnerships with biotechnology and research firms. This competitive landscape is set to create numerous opportunities for stakeholders, thereby fueling market expansion.

Restraints in the Global Liver Cirrhosis Treatment Market

The Global Liver Cirrhosis Treatment market faces several significant challenges that impede its growth. The high costs associated with medications, procedures, and surgeries necessary for effective liver disease management are primary factors hindering market development. Limited healthcare access, particularly in rural and underserved regions, contributes to this issue, compounded by a general lack of awareness around liver diseases and their symptoms among both the public and healthcare providers. Additionally, the stigma surrounding certain liver conditions, such as those linked to alcohol or bacterial infections, further complicates matters. Furthermore, the difficulties associated with liver transplantation, strict regulatory requirements, and a shortage of innovative drugs in the research and development pipeline also restrict market advancement. The substantial financial burden required for treatment adds to the overarching market restraints.

Market Trends of the Global Liver Cirrhosis Treatment Market

The Global Liver Cirrhosis Treatment market is witnessing significant growth driven by a surge in research and development aimed at new therapeutic solutions and improved diagnostic techniques. Factors such as heightened awareness of liver diseases, preventive services, and funding for treatment underscore the urgency for early diagnosis and management of these conditions. Additionally, demographic shifts with an aging population, improved healthcare infrastructure, and rising disposable incomes in emerging markets contribute to market expansion. Advancements in surgical procedures and non-invasive radiology interventions further enhance treatment options, collectively fostering a robust environment for innovative liver disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Liver Cirrhosis Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Alcoholic Cirrhosis
• Atrophic Cirrhosis
• Biliary Cirrhosis
• Cryptogenic Cirrhosis

Global Liver Cirrhosis Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Immunosuppressants
• Antibiotics
• Vaccines
• Anti-viral drugs
• Corticosteroids

Global Liver Cirrhosis Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Other

Global Liver Cirrhosis Treatment Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, End User)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Gilead Sciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viking Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galectin Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akero Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NGM Biopharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Poxel SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations